CT-03 Phase 2 trial of induction therapy with anti-CD20 (rituximab) followed by maintenance therapy with anti-BAFF (belimumab) in patients with active lupus nephritis

Cynthia Aranow, Maria Dall'Era, Margie Byron, Linna Ding, Dawn Smilek, Betty Diamond, David Wofsy, on behalf of the CALIBRATE investigators and Lupus Nephritis Trials Network
2018 Clinical Trials   unpublished
patients in histologic remission are candidates for withdrawal of therapy. Trial registration ClinicalTrial. gov, NCT02313974 Abstract CT-02 Figure 1 Persistent histologic activity on repeat biopsy after clinical remission is associated with renal flare after withdrawal of maintenance immunosuppression
doi:10.1136/lupus-2018-lsm.75 fatcat:5fljfyxw3zf7dnn2n3erphm3ji